A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
0
Authors
Donald O’Rourke
Donald O’Rourke•MacLean Nasrallah•Marcela Maus
Published
July 19, 2017
Abstract
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.
